DNA Polymerase Technology Inc.

St. Louis, MO

UEI
NJ3KC28W8NQ7
CAGE
4WUQ7
Primary NAICS
325413 In-Vitro Diagnostic Substance Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Subchapter S Corporation
  • Self Certified Small Disadvantaged Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1040 S Taylor Ave, St. Louis, MO 63110, USA
Website
klentaq.com
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Robust and fast TAQ mutants designed for direct and rapid point of care tests R43GM128532 National Institute of General Medical Sciences (NIH) $149,711
Sbir phase II: inhibition-resistant DNA polymerases and other improvements for detection of food-borne pathogens. 1127479 National Science Foundation $500,000
Direct RT-PCR detection of RNA pathogens and mrna expression in crude samples R43GM088948 National Institutes of Health $105,905
Direct RT-PCR detection of RNA pathogens in crude samples R44GM088948 National Institute of General Medical Sciences (NIH) $898,896
Sbir phase i: inhibition-resistant DNA polymerases and other improvements for detection of food-borne pathogens. 0945089 National Science Foundation $142,505

Latest 5 listed here. See the rest on GovTribe.

SBA capabilities narrative

From the vendor's SBA profile

We develop and sell DNA polymerases that are highly sensitive and able to overcome inhibitors to the polymerase chain reaction.

Quick answers

Is DNA Polymerase Technology Inc. registered in SAM.gov?

Yes. DNA Polymerase Technology Inc.'s SAM.gov registration is active through October 7, 2027.

What is DNA Polymerase Technology Inc.'s most recent federal award?

DNA Polymerase Technology Inc.'s most recent federal grant award is Robust and fast TAQ mutants designed for direct and rapid point of care tests (R43GM128532), from National Institute of General Medical Sciences (NIH), on September 15, 2018.

On GovTribe

See DNA Polymerase Technology Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login